Advanced Glycation End Product 3 (AGE3) Suppresses the Mineralization of Mouse Stromal ST2 Cells and Human Mesenchymal Stem Cells by Increasing TGF-β Expression and Secretion
Clicks: 141
ID: 269610
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
141 views
19 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #125 of 213 articles by views in endocrinology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 213 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
In diabetic patients, advanced glycation end products (AGEs) cause bone fragility because of deterioration of bone quality. We previously showed that AGEs suppr
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (23 words).
Try re-searching for a better abstract.
| Reference Key |
masakazu2014endocrinologyadvanced
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Notsu, Masakazu;Yamaguchi, Toru;Okazaki, Kyoko;Tanaka, Ken-ichiro;Ogawa, Noriko;Kanazawa, Ippei;Sugimoto, Toshitsugu; |
| Journal | endocrinology |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.